Immunomodulatory Potential of anti-idiotypic Antibodies for the Treatment of Autoimmune Diseases

References

• SarojP , VermaM , JhaKK , PalM. An overview on immunomodulation. J. Adv. Sci. Res.3, 7–12 (2012).
   Google Scholar
• SchwartzRH. Historical overview of immunological tolerance. Cold Spring Harb. Perspect. Biol.4(4), a006908 (2012).
   PubMed Web of Science ®Google Scholar
• KarimMY , PisoniCN , KhamashtaMA. Update on immunotherapy for systemic lupus erythematosus – what’s hot and what’s not!Rheumatology48, 332–341 (2009).
   PubMed Web of Science ®Google Scholar
• MillerE. Immunosuppressive therapy in the treatment of immune-mediated disease. J. Vet. Intern. Med.6, 206–213 (1992).
   PubMed Web of Science ®Google Scholar
• SilvestrisF , BankhurstAD , SearlesRP , WilliamsRCJr. Studies of anti-f (ab’) 2 antibodies and possible immunologic control mechanisms in systemic lupus erythematosus. Arthritis Rheum.27(12), 1387–1396 (1984).
   PubMedGoogle Scholar
• BedulevaL , MenshikovI , StolyarovaEet al.Rheumatoid factor in idiotypic regulation of autoimmunity. Int. J. Rheum. Dis.18, 408–420 (2015).
   PubMed Web of Science ®Google Scholar
• OakS , GilliamLK , Landin-OlssonMet al.The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines Type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A.105, 5471–5476 (2008).
   PubMed Web of Science ®Google Scholar
• AbdouNI , SuenagaR , HatfieldM , EvansM , HassaneinKM. Antiidiotypic antibodies against anti-DNA antibodies in sera of families of lupus patients. J. Clin. Immunol.9, 16–21 (1989).
   PubMed Web of Science ®Google Scholar
• von HerrathM , SandaS , HeroldK. Type 1 diabetes as a relapsing-remitting disease?Nat. Rev. Immunol.7, 988–994 (2007).
   PubMed Web of Science ®Google Scholar
• GorczynskiR , HoffmannG. Toward a new kind of vaccine: a logical extension of the symmetrical immune network theory. Interact. J. Med. Res.6, e8 (2017).
   PubMedGoogle Scholar
• Bhattacharya-ChatterjeeM , ChatterjeeSK , FoonKA. Anti-idiotype vaccine against cancer. Immunol. Lett.74, 51–58 (2000).
   PubMed Web of Science ®Google Scholar
• VázquezAMH , Rodrèguez-ZhurbenkoN , LópezAMV. Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry. Front. Oncol.2, 1–11 (2012).
   Google Scholar
• ParsonsMS , CenterRJ , RoutyJ-Pet al.Antibody responses to human immunodeficiency virus envelope from infections with multiple subtypes utilise the 1F7-idiotypic repertoire. AIDS Res. Hum. Retroviruses29, 778–783 (2013).
   PubMed Web of Science ®Google Scholar
• ViswanathD. Understanding autoimmune diseases – a review. J. Dent. Med. Sci.6, 8–15 (2013).
   Google Scholar
• CastroC , GourleyM. Diagnostic testing and interpretation of tests for autoimmunity. J. Allergy Clin. Immunol.125, S238–S247 (2010).
   PubMed Web of Science ®Google Scholar
• SuurmondJ , DiamondB. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J. Clin. Invest.125, 2194–2202 (2015).
   PubMed Web of Science ®Google Scholar
• Fridkis-HareliM. Immunogenetic mechanisms for the coexistence of organ-specific and systemic autoimmune diseases. J. Autoimmune Dis.5, 1 (2008).
   PubMedGoogle Scholar
• KronenbergHM. Polyglandular disorders. In: Goldman’s Cecil Medicine (24th Edition).GoldmanL, ShaferAI ( Eds). Elsevier, PA, USA, 1505–1509 (2012).
   Google Scholar
• CaforioALP , MalipieroG , MarcolongoR , IlicetoS. Organ-specific autoimmunity involvement in cardiovascular disease. In: Handbook of Systemic Autoimmune Diseases.AtzeniF, DoriaA, NurmohamedM, PaulettoP ( Eds). Elsevier, Cambridge, MA, 31–62 (2017).
   Google Scholar
• RayS , SonthaliaN , KunduS , GangulyS. Autoimmune disorders: an overview of molecular and cellular basis in today’s perspective. J. Clin. Cell. Immunol.10, 3 (2012).
   Google Scholar
• GerosaM , PenattiA , TedescoF , MeroniPL. Autoantibodies – future trends. Autoantibodies (3rd Edition).ShoenfeldY, MeroniPL, GershwinME ( Eds). Elsevier, Oxford, UK, 825–828 (2014).
   Google Scholar
• ShererY , GorsteinA , FritzlerMJ , ShoenfeldY. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum.34, 501–537 (2004).
   PubMed Web of Science ®Google Scholar
• MaetzelA , WongA , StrandV , TugwellP , WellsG , BombardierC. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology39, 975–981 (2000).
   PubMed Web of Science ®Google Scholar
• AletahaD , SmolenJS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J. Rheumatol.29, 1631–1638 (2002).
   PubMed Web of Science ®Google Scholar
• vander Kooij SM , DeVries-Bouwstra JK , Goekoop-RuitermanYPMet al.Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann. Rheum. Dis.66, 1356–1362 (2007).
   PubMedGoogle Scholar
• TeacheyDT , LambertMP. Diagnosis and management of autoimmune cytopenias in childhood. Pediatr. Clin. North Am.60, 1489–1511 (2013).
   PubMed Web of Science ®Google Scholar
• vanden Brand JaJG , van DijkPR , HofstraJM , WetzelsJFM. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol.9, 1066–1073 (2014).
   PubMed Web of Science ®Google Scholar
• CalatroniM , BuzioC , VaglioA. The evolving paradigm of cancer risk related to cyclophosphamide therapy in granulomatosis with polyangiitis. Rheumatology54, 1339–1341 (2015).
   PubMed Web of Science ®Google Scholar
• FeldmannM , SteinmanL. Design of effective immunotherapy for human autoimmunity. Nature435, 612–619 (2005).
   PubMed Web of Science ®Google Scholar
• CaspiRR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol.8, 970–976 (2008).
   PubMed Web of Science ®Google Scholar
• AntoniC , BraunJ. Side effects of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol.20(6; Suppl. 28), S152 (2002).
   PubMed Web of Science ®Google Scholar
• DaigleishAG , KennedyRC. Anti-idiotypic antibodies as immunogens: idiotype-based vaccines. Vaccine6, 215–220 (1988).
   PubMed Web of Science ®Google Scholar
• Bhattacharya-ChatterjeeM , ChatterjeeSK , FoonKA. The anti-idiotype vaccines for immunotherapy. Curr. Opin. Mol. Ther.3, 63–69 (2001).
   PubMedGoogle Scholar
• MccarthyH , OttensmeierCH , HamblinTJ , StevensonFK. Anti-idiotype vaccines. Br. J. Haematol.123, 770–781 (2003).
   PubMed Web of Science ®Google Scholar
• SpertiniF , LeimgruberA , MorelBet al.Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J. Rheumatol.26, 2602–2608 (1999).
   PubMed Web of Science ®Google Scholar
• LeeCH , SuhCH , LeeJ , KimYT , LeeSK. The effects of anti-idiotypic antibody on antibody production and apoptosis of anti-dsDNA antibody producing cells. Clin. Exp. Rheumatol.21, 291–300 (2003).
   PubMed Web of Science ®Google Scholar
• PaschkeR , TeuberJ , EngerI , SchmeidlR , SchwedesU , UsadelKH. Evidence for a role of anti-idiotypic antibodies in the induction of remission in Graves’ disease. J. Autoimmun.3(4), 441–448 (1990).
   PubMed Web of Science ®Google Scholar
• SikorskaHM. Anti-thyroglobulin anti-idiotypic antibodies in sera of patients with Hashimoto’s thyroiditis and Graves’ disease. J. Immunol.137(12), 3786–3795 (1986).
   PubMed Web of Science ®Google Scholar
• SongYW , KangEH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. Q. J. Med.103, 139–146 (2009).
   Google Scholar
• IngegnoliF , CastelliR , GualtierottiR. Rheumatoid factors: clinical applications. Dis. Markers35, 727–734 (2013).
   PubMed Web of Science ®Google Scholar
• HampeCS. Protective role of anti-idiotypic antibodies in autoimmunity – lessons for Type 1 diabetes. Autoimmunity45, 320–331 (2012).
   PubMed Web of Science ®Google Scholar
• Kieber-EmmonsT , Monzavi-KarbassiB , PashovA , SahaS , MuraliR , KohlerH. The promise of the anti-idiotype concept. Front. Oncol.2, 1–12 (2012).
   Google Scholar
• JerneNK. Towards a network theory of the immune system. Annales d’immunologie125C, 373–389 (1974).
   PubMedGoogle Scholar
• UnerA , GavalchinJ. Idiotypes. In: Encyclopedia of Life Sciences.Wiley, 1–5 (2006).
   Google Scholar
• LemkeH. Idiotype network. Encyclopedic Reference of Immunotoxicology.VohrH-W ( Ed.). Bayer HealthCare AG, Wuppertal, Germany, 307–311 (2005).
   Google Scholar
• ShoenfeldY. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat. Med.10, 17–18 (2004).
   PubMed Web of Science ®Google Scholar
• Bhattacharya-ChatterjeeM , ChatterjeeSK , FoonKA. Anti-idiotype antibody vaccine therapy for cancer. Expert Opin. Biol. Ther.2, 869–881 (2002).
   PubMed Web of Science ®Google Scholar
• LadjemiMZ. Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements. Front. Oncol.2, 1–8 (2012).
   Google Scholar
• NaveedA , RahmanSU , ArshadMI , AslamB. Recapitulation of the anti-idiotype antibodies as vaccine candidate. Transl. Med. Comm.3, 1–7 (2018).
   Google Scholar
• StanovaAK , RyabkovaVA , UtekhinSV , ShoenfeldVJ , ChurilovLP , ShoenfeldY. Anti-idiotypic agonistic antibodies: candidates for the role of universal remedy. Antibodies (Basel)9(2), (2020).
   PubMedGoogle Scholar
• LawrenceTG , WilliamsRC. Studies of human anti-γ-globulin factors reacting with pepsin-digested γ-globulins. J. Exp. Med.125, 233–248 (1967).
   PubMed Web of Science ®Google Scholar
• StaffordHA , AndersonCJ , ReichlinM. Unmasking of anti-ribosomal P autoantibodies in healthy individuals. J. Immunol.155, 2754–2761 (1995).
   PubMed Web of Science ®Google Scholar
• PanZJ , AndersonCJ , StaffordHA. Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults. J. Clin. Invest.102, 215–222 (1998).
   PubMed Web of Science ®Google Scholar
• KohlerH , PashovA , Kieber-EmmonsT. The promise of anti-idiotype revisited. Front. Immunol.10, 1–7 (2019).
   PubMed Web of Science ®Google Scholar
• ZanettiM. Anti-idiotypic antibodies and autoantibodies. Ann. N. Y. Acad. Sci.418, 363–378 (1983).
   PubMed Web of Science ®Google Scholar
• WilliamsWM , IsenbergDA. Naturally occurring anti-idiotypic antibodies reactive with anti-DNA antibodies in systemic lupus erythematosus. Lupus7, 164–175 (1998).
   PubMed Web of Science ®Google Scholar
• MaJ , ZhouL , WangD. Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response. Jpn J. Cancer Res.01, 78–84 (2002).
   Google Scholar
• LiG , XieL , ZhouG , FuH , ZhouJ , SunQ. A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients. Chin. Med. J.115, 567–570 (2002).
   PubMed Web of Science ®Google Scholar
• GaidaFJ , FengerU. A monoclonal anti-idiotypic antibody bearing the image of an epitope specific to the human carcinoembryonic antigen. Int. J. Cancer51(3), 459–465 (1992).
   PubMed Web of Science ®Google Scholar
• López-RequenaA , BurroneOR. Anti-idiotypic antibodies and “tumor-only” antigens: an update. Open Immunol. J.2(1), 1–8 (2009).
   Google Scholar
• ArbuckleMR , McClainMT , RubertoneMVet al.Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med.349, 1526–1533 (2003).
   PubMed Web of Science ®Google Scholar
• TerBorg EJ , HorstG , HummelEJ , LimburgPC , KallenbergCGM. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum.33, 634–643 (1990).
   PubMedGoogle Scholar
• YungS , ChanTM. Mechanisms of kidney injury in lupus nephritis – the role of anti-dsDNA antibodies. Front. Immunol6, 1–11 (2015).
   PubMed Web of Science ®Google Scholar
• HeinlenLD , RitterhouseLL , McClainMTet al.Ribosomal P autoantibodies are present before SLE onset and are directed against non-C terminal peptides. J. Mol. Med.88, 719–727 (2011).
   Web of Science ®Google Scholar
• MartinAL , ReichlinM. Fluctuations of antibody to ribosomal P proteins correlate with appearance and remission of nephritis in SLE. Lupus5, 22–29 (1996).
   PubMed Web of Science ®Google Scholar
• AbdouNI , WallH , LindsleyHB , HalseyJF , SuzukiT. Network theory in autoimmunity. In vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus. J. Clin. Invest.67, 1297–1304 (1981).
   PubMed Web of Science ®Google Scholar
• PanZJ , AndersonC , StaffordH. Dysfunction of anti-idiotypic antibodies to anti-ribosomal P in SLE patients. Arthritis Rheum.41(9), S253 (1998).
   Google Scholar
• PanZJ , AndersonCJ , StaffordHA. A murine monoclonal anti-idiotype to anti-ribosomal P antibodies: production, characterisation, and use in systemic lupus erythematosus. Clin. Immunol.100, 289–297 (2001).
   PubMed Web of Science ®Google Scholar
• ZhangW , WinklerT , KaldenReichlin JR. Isolation of human anti-idiotypes broadly cross reactive with anti-dsDNA antibodies from patients with systemic lupus erythematosus. Scand. J. Immunol.53, 192–197 (2001).
   PubMed Web of Science ®Google Scholar
• WeisbartRH , NoritakeDT , WongALet al.A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus. J. Immunol.144, 2653–2658 (1990).
   PubMed Web of Science ®Google Scholar
• GregersenPK , SilverJ , WinchesterRJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum.30, 1205–1213 (1987).
   PubMed Web of Science ®Google Scholar
• CopeAP. Rheumatoid arthritis. In: Clinical Immunology: Principle and Practice(5th Edition).RichRR, FleisherTA, ShearerWT, SchroederHW, FrewAJ, WeyandCM ( Eds). Elsevier, London, UK, 705–721.e701 (2019).
   Google Scholar
• NielenMMJ , Van SchaardenburgD , ReesinkHWet al.Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum.50, 380–386 (2004).
   PubMed Web of Science ®Google Scholar
• McinnesIB , SchettG. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med.365, 2205–2219 (2011).
   PubMed Web of Science ®Google Scholar
• KokkonenH , JohanssonM , InnalaL , JidellE , Rantapää-DahlqvistS. Erratum: the PTPN221858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res. Ther.9, R56 (2007).
   PubMed Web of Science ®Google Scholar
• DörnerT , EgererK , FeistE , BurmesterGR. Rheumatoid factor revisited. Curr. Opin. Rheumatol.16, 246–253 (2004).
   PubMed Web of Science ®Google Scholar
• MooreTL , OsbornTG , DornerRW. Cross-reactive antiidiotypic antibodies against human rheumatoid factors from patients with juvenile rheumatoid arthritis. Arthritis Rheum.32, 699–705 (1989).
   PubMedGoogle Scholar
• TakeuchiT , HosonoO , KoideJ , HommaM , AbeT. Suppression of rheumatoid factor synthesis by antiidiotypic antibody in rheumatoid arthritis patients with cross-reactive idiotypes. Arthritis Rheum.28, 873–881 (1985).
   PubMedGoogle Scholar
• JiangW , MacmillanH , MadecAM , MellinsED. Optimized purification strategies for the elimination of non-specific products in the isolation of GAD65-specific monoclonal autoantibodies. F1000 Research4, 1–13 (2016).
   Google Scholar
• TaplinCE , BarkerJM. Autoantibodies in Type 1 diabetes. Autoimmunity41, 11–18 (2008).
   PubMed Web of Science ®Google Scholar
• BaschalEE , AlyTA , BabuSRet al.HLA-DPB1* 0402 protects against Type 1A diabetes autoimmunity in the highest risk DR3-DQB1* 0201/DR4-DQB1* 0302 DAISY population. Diabetes56, 2405–2409 (2007).
   PubMed Web of Science ®Google Scholar
• TownsR , PietropaoloM. GAD65 autoantibodies and its role as biomarker of Type 1 diabetes and latent autoimmune diabetes in adults (LADA). Drugs Future36, 847 (2011).
   PubMed Web of Science ®Google Scholar
• LarssonHE , JönssonI , LernmarkÅ , IvarssonS , RadtkeJR , HampeCS. Decline in titers of anti-idiotypic antibodies specific to autoantibodies to GAD65 (GAD65Ab) precedes development of GAD65Ab and Type 1 diabetes. PLoS One8(6), e65173 (2013).
   PubMed Web of Science ®Google Scholar
• WangX , ZhangA , LiuYet al.Anti-idiotypic antibody specific to GAD65 autoantibody prevents Type 1 diabetes in the NOD mouse. PLoS One7, 4–11 (2012).
   Web of Science ®Google Scholar
• GramschC , SchulzR , KosinS , HerzA. Monoclonal anti-idiotypic antibodies to opioid receptors. J. Biol. Chem.263(12), 5853–5859 (1988).
   PubMed Web of Science ®Google Scholar
• NelsonK , GeorgeE , SwensonC , ForstromJ , HellströmK. Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells. J. Immunol.139(6), 2110–2117 (1987).
   PubMed Web of Science ®Google Scholar
• DurrantLG , DoranM , AustinEB , RobinsRA. Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognising the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours. Int. J. Cancer61(1), 62–66 (1995).
   PubMed Web of Science ®Google Scholar
• AlfonsoS , DiazRM , dela Torre Aet al.1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biology Therapy6(12), 1847–1852 (2007).
   PubMed Web of Science ®Google Scholar
• HiganoCS , SmallEJ , SchellhammerPet al.Sipuleucel-T. Nat. Rev. Drug Discov.9(7), 513–514 (2010).
   PubMed Web of Science ®Google Scholar
• FDA approval for Unituxin for pediatric high-risk neuroblastoma. Oncology Times37(7), 4 (2015).
   Google Scholar
• ElAmrani M , SzantoCL , HackCE , HuitemaADR , NierkensS , Van MaarseveenEM. Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry. Anal. Bioanal. Chem.410(23), 5849–5858 (2018).
   PubMed Web of Science ®Google Scholar
• ÖzkaynakMF. Dinutuximab in the treatment of neuroblastoma. Expert Opin. Orphan Drugs5(3), 277–284 (2017).
   Web of Science ®Google Scholar
• MittelmanA , ChenZ , KageshitaTet al.Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J. Clin. Investig.86(6), 2136–2144 (1990).
   PubMed Web of Science ®Google Scholar
• ParrayHA , ShuklaS , SamalSet al.Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int. Immunopharmacol.85, 106639 (2020).
   PubMed Web of Science ®Google Scholar
• FoonKA , ChakrabortyM , JohnWJ , SherrattA , KöhlerH , Bhattacharya-ChatterjeeM. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Investig.96(1), 334–342 (1995).
   PubMed Web of Science ®Google Scholar
• LipmanNS , JacksonLR , TrudelLJ , Weis-GarciaF. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J.46(3), 258–268 (2005).
   PubMed Web of Science ®Google Scholar
• BasakS , EckS , GutzmerRet al.Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector. Ann. N. Y. Acad. Sci.910(1), 237–253 (2000).
   PubMedGoogle Scholar
• VoskuilJ. Commercial antibodies and their validation. F1000 Research3(232), 1–12 (2014).
   PubMedGoogle Scholar